Puma Biotechnology (PBYI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	55.63 mm	55.63 mm	55.63 mm	55.63 mm	55.63 mm	55.63 mm
Cash burn (monthly)	379.00 k	1.14 mm	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	889.81 k	2.69 mm	n/a	n/a	n/a	n/a
Cash remaining	54.74 mm	52.94 mm	n/a	n/a	n/a	n/a
Runway (months of cash)	144.4	46.2	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

PBYI institutional ownership history Ownership history

65.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	112	105	+6.7%
Opened positions	25	19	+31.6%
Closed positions	18	17	+5.9%
Increased positions	48	34	+41.2%
Reduced positions	19	23	-17.4%

13F shares	Current	Prev Q	Change
Total value	82.16 bn	70.21 bn	+17.0%
Total shares	32.90 mm	35.83 mm	-8.2%
Total puts	3.40 k	16.30 k	-79.1%
Total calls	27.90 k	50.60 k	-44.9%
Total put/call ratio	0.1	0.3	-62.2%

Largest owners	Shares	Value	Change
BlackRock	3.82 mm	$11.66 bn	-0.1%
Vanguard	3.64 mm	$11.11 bn	+0.2%
Acorn Capital Advisors	2.45 mm	$12.02 bn	NEW
Acorn Bioventures	2.29 mm	$6.95 mm	+20.1%
Integrated Core Strategies	2.00 mm	$7.22 mm	0.0%
Acadian Asset Management	1.97 mm	$6.01 mm	+0.2%
Millennium Management	1.89 mm	$5.78 bn	-34.3%
Renaissance Technologies	1.76 mm	$5.35 bn	-1.0%
Eversept Partners	996.10 k	$3.04 bn	-23.0%
American Century Companies	948.38 k	$2.89 bn	+8.4%

Largest transactions	Shares	Bought/sold	Change
Frazier Life Sciences Management	0.00	-3.06 mm	EXIT
Acorn Capital Advisors	2.45 mm	+2.45 mm	NEW
Frazier Life Sciences Public Fund	0.00	-1.30 mm	EXIT
Athyrium Capital Management	0.00	-1.26 mm	EXIT
Millennium Management	1.89 mm	-986.76 k	-34.3%
Acorn Bioventures	2.29 mm	+383.16 k	+20.1%
Eversept Partners	996.10 k	-297.15 k	-23.0%
WINTON	38.24 k	-270.74 k	-87.6%
Affinity Asset Advisors	0.00	-250.00 k	EXIT
Kennedy Capital Management	809.38 k	+216.33 k	+36.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PBYI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Nov 25	Miller Michael Patrick	Common Stock	Sell	Dispose S	No	No	4.8614	20,000	97.23 k	54,000
18 Jul 25	Alessandra Cesano	Common Stock	Sell	Dispose S	No	Yes	3.367	27,000	90.91 k	41,850
9 Jul 25	Auerbach Alan H	Common Stock	Sell	Dispose S	No	Yes	3.535	21,580	76.29 k	7,180,901
9 Jul 25	Douglas M Hunt	Common Stock	Sell	Dispose S	No	Yes	3.535	3,443	12.17 k	164,894
9 Jul 25	Maximo F Nougues	Common Stock	Sell	Dispose S	No	Yes	3.535	3,935	13.91 k	204,229
8 Jul 25	Auerbach Alan H	Common Stock	Sell	Dispose S	No	Yes	3.533	25,592	90.42 k	7,202,481
8 Jul 25	Douglas M Hunt	Common Stock	Sell	Dispose S	No	Yes	3.533	4,374	15.45 k	168,337
8 Jul 25	Maximo F Nougues	Common Stock	Sell	Dispose S	No	Yes	3.533	5,587	19.74 k	208,164

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Intraday Session

10 Nov 25

Earnings Scheduled For November 6, 2025

6 Nov 25

Press releases

From Benzinga Pro

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 Dec 25

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

7 Nov 25

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 Oct 25

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit